🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fujimoto et al - Allo / auto in ENKT? Japanese data. • if in CR, ASCT appear superior to allo • if in PR, allo appears preferable • no impact on source of allo cells I normally allo these pts in CR1 so potentially practise changing. #18ICML #ICML25 #lymsm

More evidence for the use of PD1 inhibition and XRT in early stage ENKTL from Won Seog Kim, following the earlier presentation from IELSG50. Interesting to see a lower dose of XRT (40 Gy cf 50+ Gy) here - will be looking out for longer term followup.

CONGRESS | #18ICML | PRESENTATION Matthew S. Davids Matthew Davids, MD, MMSc Dana-Farber discusses the primary endpoint evaluation from a phase II study of venetoclax plus R-CHOP for the treatment of patients with Richter’s Syndrome. A median PFS of 16.2 months, median OS not reached, 2-year

CONGRESS | #18ICML | PRESENTATION Ali Bazarbachi discusses an analysis from the EBMT Lymphoma Working Party of outcomes following CAR-T versus auto-HSCT in patients with large B-cell lymphoma in CR. There were no significant differences between CAR-T and auto-HSCT for OS, PFS,

CONGRESS | #18ICML | PRESENTATION Juan Pablo Alderuccio Juan P. Alderuccio Sylvester Comprehensive Cancer Center presents the initial results from LOTIS-7, evaluating loncastuximab tesirine plus glofitamab in patients with R/R #DLBCL. ORR across all dose levels 93.3%, with a CR rate of 86.7%. Most

Problem: these classification tools are not accessible to vast majority of oncologists (particularly in the community where majority of DLBCL is treated). Very challenging to say from the podium that we should be doing this in routine clinical practice. #lymsm #18ICML 1/

Ajay Major, MD, MBA For our friends and our colleagues, especially those in community oncology, if you had the proverbial gun to your head, and you really had to chose between either MRD at End of Rx vs any or all of these various genetic classifiers to define 5/6/7/8 DLBCL subtypes as proposed by

Dr Teresa Calimeri presents an The EBMT registry study in PCNSL. No difference in PFS in CR vs. PR pre-ASCT found (also seen in IELSG32). Interestingly, 2y PFS was 50% in 49 patients in PD pre-ASCT. Do we need more sensitive response assessment methods? #18icml

CONGRESS | #18ICML | PRESENTATION Christopher Fox Chris Fox Uni of Nottingham #WeAreUoN presents results from Cohort 1 of the phase II PRiZM+ study assessing the safety and efficacy of the zanubrutinib monotherapy in patients with R/R PCNSL (N = 20). The ORR at 8 weeks was 50%, with a

CONGRESS | #18ICML | PRESENTATION Patrick B Johnston, Mayo Clinic highlights results from the phase II DAILY II US trial of zamtocabtagene autoleucel in patients with R/R CNSL (N = 16). Zamto-cel was well tolerated in patients with R/R CNSL, with encouraging efficacy (ORR,

CONGRESS | #18ICML | PRESENTATION Kate Cwynarski Kate Cwynarski UCLH presents 7-year follow-up results from the phase II MARIETTA trial of multi-agent chemotherapy with MATRix and R-ICE followed by TT-ASCT in patients with SCNSL (N = 75). Long-term follow-up results demonstrate

1/ Excellent news for 🇺🇸 patients receiving CAR-T therapy! FDA has listened to data and relaxed CRS monitoring and driving restrictions for liso-cel for #lymsm / ide-cel for #MMsm. Huge step to lower time toxicity and disparities. Can this be fixed for all CAR-T products?

Congratulations to our Class of 2025 Hematology/Oncology Fellowship Graduates at UC Irvine ! Brian Warnecke, Sami Dwabe, Omid Yazdanpanah, and Nghia (Michael) Pham: Thank you for elevating the level of our program over the past 3 years. You are well-trained and ready to embark

Vincent Rajkumar Ahmed Kotb Al-Ola A Abdallah MD (USMIRC) 4/ Rahul Banerjee, MD, FACP on real world data from the US MM Immunotherapy Consortium: x.com/RahulBanerjeeM…

1/ Why is Ki-67 called Ki-67? And why am I attaching a photo of this beautiful city to the tweet? If you work in pathology or oncology, you’ve likely come across Ki-67 many times. But where does the name come from? A short 🧵 on the origins, function, and significance of Ki-67.

📢 Out in NEJM Evidence 👫N=1132 pts; age 18-60 🔹ND #AML 🔹Consolidation with IDAC vs HIDAC 🔹5-yr OS = 59% vs 58% 🔹Lower incidence of myelosuppressio & AEs with IDAC ➡️ IDAC non inferior to HIDAC #leusm OncoAlert evidence.nejm.org/doi/pdf/10.105…

Why do many regulatory oncology phase III trials not accrue sufficient US patients? This issue came up repeatedly at today’s ODAC for belantamab for myeloma. And I can address it at least for myeloma. 1) In our healthcare system, opening a trial in a timely manner is a

Bispecifics in R/R LBCL Blood Journals Portfolio: - 245 pts, 64% epcor, 60% prior CAR - mPFS 2.5 mos (!!!): 2.3 epcor, 3.8 glofi - mOS 7.8 mos overall (in MV model, glofi = better OS) - worse PFS/OS if trial ineligible & w/i 90 d of CAR Outcomes not great. #lymsm ashpublications.org/blood/article/…

1/ Our call to action is out in Blood Advances! Title speaks for itself. Given concerningly high infection risk with bsAbs in myeloma #MMsm, IVIG/SCIG should be started regardless of any IgG threshold. Global authors & global audience, including insurance & healthcare funders.

HGBCL-NOS: We identify another histology with relatively CAR resistant relapse. N=111, most axi-cel, 2 year OS and PFS 42% and 29%. NRM 3%. #lymsm #cibmtr BJH | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…